<DOC>
	<DOCNO>NCT00056693</DOCNO>
	<brief_summary>To assess safety efficacy SU11248 patient Neuroendocrine Tumors .</brief_summary>
	<brief_title>Treatment With SU11248 Patients With Neuroendocrine Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologically cytologically proven diagnosis carcinoid tumor pancreatic islet cell tumor . Evidence unidimensionally measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) . ECOG performance status 0 1 Diagnosis smallcell carcinoma , pheochromocytoma/paraganglioma , Merkel cell carcinoma , second malignancy within last 5 year except adequately treat basal cell squamous cell skin cancer , situ carcinoma cervix uterus . Prior treatment tyrosine kinase inhibitor antiVEGF angiogenic inhibitor . Prior treatment nonVEGFtargeted angiogenic inhibitor permit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Neuroendocrine tumor , advanced disease , sunitinib , Phase 2</keyword>
</DOC>